Concepedia

Author

Philip J. Gold

Swedish Medical Center

Also Known As

P GOLD, P Gold, P J Gold, P. Gold, P. J. Gold, P.J. Gold, Philip Gold, Philip J Gold, Philip J Gold,, Philip J. Gold

94

Publications

3.6K

Citations

26

H-Index

48

Concepts

All Affiliations

Swedish Medical CenterFox Chase Cancer CenterDana-Farber Cancer InstituteDuke Medical CenterThe University of Texas MD Anderson Cancer Center
PJ

About

Philip J. Gold is an author at Swedish Medical Center specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

20

1.7K

2

Immunology

7

7

324

3

Hepatology

4

4

639

4

Health Sciences

2

2

45

5

Gastroenterology

2

2

28

Philip J. Gold

×

32

Publications

3.1K

Citations

24

H-Index

YearCitations

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Heinz‐Josef Lenz, Eric Van Cutsem, Shirin Khambata‐Ford,

Journal of Clinical Oncology

2006

536

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng,

The Lancet

2023

415

UGT1A7 and UGT1A9 Polymorphisms Predict Response and Toxicity in Colorectal Cancer Patients Treated with Capecitabine/Irinotecan

Leslie E. Carlini, Neal J. Meropol, John L. Bever,

Clinical Cancer Research

2005

261

Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.

Paul B. Chapman, Tina Lester, E. S. Casper,

Journal of Clinical Oncology

1987

219

First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma

Andrew X. Zhu, Philip J. Gold, Anthony B. El-Khoueiry,

Clinical Cancer Research

2013

192

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

Daniel V.T. Catenacci, Yoon‐Koo Kang, Haeseong Park,

The Lancet Oncology

2020

186

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

Anthony B. El-Khoueiry, Cathryn Rankin, Edgar Ben‐Josef,

Investigational New Drugs

2011

167

Paraneoplastic manifestations of renal cell carcinoma

Nehal Masood, Philip J. Gold, John A.Thompson

2003

150

Thymidine Phosphorylase Expression Is Associated With Response to Capecitabine Plus Irinotecan in Patients With Metastatic Colorectal Cancer

Neal J. Meropol, Philip J. Gold, Robert B. Diasio,

Journal of Clinical Oncology

2006

110

Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin

Heinz‐Josef Lenz, Robert J. Mayer, Philip J. Gold,

Journal of Clinical Oncology

2004

96

Page 1